The First-in-Class Paradox: Executive Summary

Read the full article at: https://quanthealth.ai/resources/the-first-in-class-paradox

First-in-class drug programs face a core paradox — predicting how a novel therapeutic will perform in patients when no clinical precedent exists.

The Challenge: Traditional tools (statistical models, preclinical data, expert judgment) can frame and reduce this uncertainty, but quantitative estimates remain sensitive to the available evidence.

The Solution: A shift from subjective estimation alone to multi-layered, AI-driven simulation, built on three pillars:

1. 1. Multi-Model Integration: Combining mechanistic biology models, Bayesian/probabilistic methods, and machine learning/generative AI into one framework, enabling rapid simulation of hundreds of trial scenarios.

   2. Learning Without Clinical History: Life sciences needs a system that compensates for a lack of trial data on the novel asset by drawing on two other data sources:

      o Real-world data from patient journeys, used to build patient-level embeddings.

      o A biomedical knowledge graph mapping drugs, targets, pathways, and diseases, from which graph neural networks generate embeddings for the new asset.

       

      Fusing these embeddings in a transformer-based model (LRDM) is designed to support outcome prediction even for mechanisms with zero prior clinical data, subject to appropriate extrapolation validation.
   3. From Prediction to Optimization: Simulation outputs go beyond a go/no-go signal, providing a baseline probability of success plus iterative stress-testing that identifies trial design improvements (inclusion/exclusion criteria, endpoints, comparators) — potentially revealing that failure risk lies partly in trial architecture, not only biology.

Clinical trials cannot reveal every patient's counterfactual outcome and therefore, models are validated through a three-part gauntlet: retrospective testing against historical trial outcomes, blind extrapolation withholding mechanism-specific clinical outcomes, and prospective testing that locks-in time-stamped predictions publicly before a live trial reads out.

QuantHealth reports 85-90% prediction accuracy for success/failure across therapeutic areas, depending on the evaluation cohort.

Bottom Line: First-in-class programs succeed on efficacy and safety but only launch on operational and commercial feasibility. Unified simulation across clinical, operational, and commercial risk helps sponsors design trials that are scientifically sound, enrollable, and commercially viable.